Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
Year: 2016
Type: article
Study design: Clinical Trial
Abstract: PURPOSE: Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer. PATIENTS AND METHODS: A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TNM 1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA ≤ 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT. Centers opted for one dose (70, 74, or 78 Gy). Biochemical DFS, the primary end point, was defined from entry until PSA relapse (Phoenix criteria) and clinical relapse by imaging or death of any cause. The trial had 80% power to detect hazard ratio (HR), 0.714 by intent-to-treat analysis stratified by dose of RT at the two-sided α = 5%. RESULTS: The median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P < .001, with 319 events), as well as clinical progression-free survival (205 events, HR, 0.63; 95% CI, 0.48 to 0.84; P = .001). In exploratory analysis, no statistically significant interaction between treatment effect and dose of RT could be evidenced (heterogeneity P = .79 and P = .66, for biochemical DFS and progression-free survival, respectively). Overall survival data are not mature yet. CONCLUSION: Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.
Source: Journal of Clinical Oncology
Authors: Michel Bolla, Philippe Maingon, Christian Carrie, Salvador Villa, Petros Kitsios, Philip M.P. Poortmans, Santhanam Sundar, Elzbieta M. van der Steen-Banasik, John Armstrong, Jean-François Bosset, Fernanda G. Herrera, Bradley Pieters, Annerie Slot, Amit Bahl, Rahamim Ben-Yosef, Dirk Boehmer, Christopher Scrase, Laurette Renard, Emad Shash, Corneel Coens, Alphonsus C.M. van den Bergh, Laurence Collette
Language: English
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Keywords: localized prostate cancer, androgen deprivation therapy, GnRH agonist, radiation dose escalation, intermediate-risk prostate cancer, high-risk prostate cancer, biochemical recurrence, disease-free survival, prostate-specific antigen, combined androgen blockade, quality of life, sexual function, urinary incontinence
Open Access status: green
Funders: AstraZeneca, Johns Hopkins University, Health Research Board, Nottingham University Hospitals NHS Trust, University Hospitals Bristol NHS Foundation Trust, University of Nottingham, Universiteit Leiden, Rijksuniversiteit Groningen, Universiteit van Amsterdam, Radboud Universiteit, Academisch Medisch Centrum, Universitair Medisch Centrum Groningen, Radboud Universitair Medisch Centrum, Centre Hospitalier Universitaire Vaudois, Centre Léon Bérard, Cliniques Universitaires Saint-Luc
Award: G9000370754
OpenAlex ID: W2296809578
